Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information


EU orphan designation number: EU/3/09/626
Active ingredient: Lintuzumab
Indication: Treatment of myelodysplastic syndromes
Sponsor: Seattle Genetics UK Limited
c/o Jordans Limited, 20-22 Bedford Row, London WC1R 4JS , United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/05/2009 Orphan designation EMEA/OD/117/08 (2009)3455 of 29/04/2009
17/08/2011 Removal of orphan designation from Community Register